<DOC>
	<DOCNO>NCT01348490</DOCNO>
	<brief_summary>To evaluate effect treatment ruxolitinib ( INCB018424 ) spleen volume , symptoms potential side effect patient PMF , PPV-MF PET-MF platelet count 50 x 10^9/L 100 x 10^9/L . It anticipate individualized dose optimization start ruxolitinib level 5 mg bid associate reduction splenomegaly , MF-associated symptom inflammatory cytokine level .</brief_summary>
	<brief_title>Ruxolitinib ( INCB018424 ) Subjects With Primary Myelofibrosis , Post Essential Thrombocythemia-myelofibrosis Post Polycythemia Vera-myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Diagnosed PMF , PPVMF PETMF confirm bone marrow biopsy Discontinuation drug use treat underlie MF disease least 7 day prior baseline visit INR &lt; 1.5 PTT value &lt; 1.5 x upper limit normal ( ULN ) study entry Hemoglobin level least 6.5 g/dL Screening visit Willingness transfuse treat low hemoglobin level Females pregnant , unable comply birth control use avoid become pregnant breastfeeding Males comply birth control use avoid fathering child Platelet count &lt; 50 x10^9/L absolute neutrophil count ( ANC ) &lt; 1 x10^9/L Screening visit Inadequate liver renal function ; Intracranial bleeds invasive malignancy previous 2 year international normalized ratio ( INR ) laboratory value &gt; 1.5 x upper limit normal study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PMF</keyword>
	<keyword>PPV-MF</keyword>
	<keyword>PET-MF</keyword>
</DOC>